Arvinas Holding Company (ARVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Derek Archila from Wells Fargo maintained a Buy rating on the stock and has a $26.00 price target.
Derek Archila has given his Buy rating due to a combination of factors related to Arvinas Holding Company’s strategic positioning and potential market opportunities. Despite the cautious outlook on vepdeg’s competitiveness until full data is available, Archila notes the company’s commitment to advancing its trials and the potential for approvable outcomes, particularly in the 2L+ ER BC market.
Furthermore, Archila acknowledges the financial stability of Arvinas, with over $1 billion in cash and a runway extending into 2027, which supports the company’s ability to fund ongoing and future trials. Despite the current market challenges and the significant drop in stock value, Archila sees potential upside due to Pfizer’s continued commitment to the program and the possibility of a New Drug Application filing, which could improve the stock’s position from its current depressed levels.
According to TipRanks, Archila is a 4-star analyst with an average return of 5.7% and a 44.54% success rate. Archila covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Exelixis, and Incyte.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $81.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com